ResMed vs Edwards Lifesciences: Which Is the Stronger Buy Today?
Even as Edwards Lifesciences surged 6.2% during the past Day, its peer ResMed may be a better choice. Consistently evaluating alternatives is core to sound investment approach. ResMed (RMD) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Edwards Lifesciences (EW) stock, suggesting you may be better off investing in RMD
- RMD’s Last 12 Months revenue growth was 9.8%, vs. EW’s 9.1%.
- In addition, its Last 3-Year Average revenue growth came in at 12.9%, ahead of EW’s 3.0%.
- RMD leads on profitability over both periods – LTM margin of 32.8% and 3-year average of 29.9%.
Trefis works with Empirical Asset Management – a Boston area wealth manager – whose asset allocation strategies yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Empirical has incorporated the Trefis HQ Portfolio in this asset allocation framework to provide clients better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
EW provides structural heart disease products, critical care, and surgical monitoring technologies, including aortic surgical valves, distributed via direct sales and independent distributors. RMD develops and markets medical devices and cloud software for healthcare, including remote monitoring systems and personalized therapy apps for sleep apnea management.
Valuation & Performance Overview
| EW | RMD | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 29.9 | 22.5 | RMD |
| Revenue Growth | |||
| Last Quarter | 11.9% | 10.2% | EW |
| Last 12 Months | 9.1% | 9.8% | RMD |
| Last 3 Year Average | 3.0% | 12.9% | RMD |
| Operating Margins | |||
| Last 12 Months | 27.9% | 32.8% | RMD |
| Last 3 Year Average | 29.5% | 29.9% | RMD |
| Momentum | |||
| Last 3 Year Return | -6.3% | 14.7% | RMD |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: EW Revenue Comparison | RMD Revenue Comparison
See more margin details: EW Operating Income Comparison | RMD Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell RMD Stock to see if ResMed’s edge holds up under the hood or if Edwards Lifesciences still has cards to play (see Buy or Sell EW Stock).
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| EW Return | 17% | 42% | -42% | 2% | -3% | 9% | -2% | ||
| RMD Return | 38% | 23% | -19% | -17% | 34% | 14% | 76% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 110% | <=== | |
| Monthly Win Rates [3] | |||||||||
| EW Win Rate | 50% | 75% | 33% | 58% | 75% | 56% | 58% | ||
| RMD Win Rate | 75% | 50% | 50% | 58% | 50% | 67% | 58% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 67% | 64% | <=== | |
| Max Drawdowns [4] | |||||||||
| EW Max Drawdown | -33% | -14% | -47% | -17% | -22% | -9% | -24% | ||
| RMD Max Drawdown | -26% | -15% | -26% | -35% | -4% | -10% | -19% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 10/27/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read RMD Dip Buyer Analyses and EW Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.